Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348632 · ClinicalTrials.gov registry record · Phase 3
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 645
- Enrollment target
NCT02348632 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 645 participants.
The verdict
NCT02348632, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 645 participants
- Enrollment target
Study Summary
This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.
Interventions
- DRUG JZP-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02348632
The ClinicalTrials.gov registry entry for NCT02348632 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 645 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JZP-110 is the first listed.
NCT02348632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02348632 about?
NCT02348632 is a clinical study titled ""A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"". This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.
What is the current status of trial NCT02348632?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 645 participants. The study started on 2015-05. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02348632?
The interventions under investigation include: JZP-110 (DRUG).
Who is sponsoring clinical trial NCT02348632?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.